Latest Manufacturing News

AnteoTech has secured independent validation for its Ultranode™ 95 silicon anode in commercial drone battery cells, launched a new battery additive, and strengthened its cash position with a A$10 million capital raise.

LTR Pharma has locked in a comprehensive commercial agreement with Strive Pharmacy, cementing its manufacturing and fulfilment infrastructure for the upcoming US launch of ROXUS®.

Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.

OncoSil Medical has gained Saudi FDA approval for its OncoSil™ device, enabling full reimbursement and commercial access in Saudi Arabia, the Middle East's largest healthcare market.

ECS Botanics delivered a fourth consecutive quarter of positive operating cash flow in Q4 FY26, with a full-year turnaround of $5.9 million. The company’s branded B2C revenue surged 31% year-on-year, supported by product launches and European market expansion.

BCI Minerals has reached 85% construction completion at its Mardie Salt Operation and Potash Project, with salt crystallisation commenced and 49,000 tonnes produced. The project remains fully funded and on budget, progressing towards first salt shipment in early 2027, weather permitting.

Boresight Ltd has secured a lease for a new 812 square metre manufacturing hub in Huntsville, Alabama, vastly expanding its US production capacity for aerial target drones amid rising military demand.

Marlin Global's portfolio delivered a 2.0% gross return in Q2 2026, driven by rebounds in ICON and semiconductor holdings, but lagged a strong US market rally led by AI and chip stocks.

Fletcher Building and the New Zealand Government have struck a $60 million deal to keep Golden Bay Cement's Northland plant operational until at least 2040, safeguarding a critical domestic supply chain and addressing carbon cost challenges.

Firebird Metals has achieved a key milestone under the ARENA Battery Breakthrough Initiative, unlocking a A$1 million non-dilutive payment and progressing site development for its Australian Demonstration Plant in Perth.

Dimerix has acquired DMX-652, a Phase 2-ready oral drug candidate targeting acute kidney injury, expanding its renal disease portfolio. The acquisition includes patent rights, an FDA-approved trial protocol, and funding to initiate clinical development.

Titomic Limited updates investors that its planned shift of corporate domicile from Australia to the US is still underway but the timeline has slipped, with a revised schedule expected by late July or August 2026.